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FLUDARABINE-BASED REDUCED-INTENSITY CONDITIONING FOR AL-
LOGENEIC TRANSPLANTATION IN CHILDREN WITH MALIGNANT AND
NON-MALIGNANT DISEASES
Gonzalez, M.1, Perez, A.1, Ramirez, M.1, Sevilla, J.1, Madero, L.1,
Diaz, M.A.1 1Hospital “Nin˜o Jesus”, Madrid, Spain.
Sixty-seven pediatric patients with malignant (n48) and non-
malignant diseases (n19) underwent seventy-three allogeneic
transplantations using ﬂudarabine-based reduced-intensity con-
ditioning (RIC) between May 2001 and June 2006. Condition-
ing regimens consisted of ﬂudarabine 30 mg/m2/day x 5 days
plus melphalan 140 mg/m2/day x 1 day (n25) or plus oral/iv
busulphan 4 mg/Kg/day x 2 days (n29) or plus cyclophosph-
amide 60 mg/kg/day x 2 days and globuline antithymocyte 2.5
mg/kg/day x 2 days (n19). The patients were grafted with bone
marrow (n13), cord blood (n10) or PBSC either unmanipu-
lated (n10) or CD34 selection (n34) or CD3/CD19 deple-
tion (n6). GVHD prophylaxis was performed with CsA Mtx
(n62), CsA only (n7) and CsA  steroids (n4). Donors
were either related (n42) or unrelated (n31). The median
number of CD34 cells infused was 5.75106/kg recipient bw
(range 0.25-47.7). Results: All patients achieved primary en-
graftment. However, eight patients developed secondary graft
failure. The probability of secondary graft failure was 145%.
There were a rapid recovery of neutrophils (median 13 days;
range 5-29) and platelets (median 15 days; range 5-56). The
median length of hospital stay was 18 days ( range 9-85). With
a median follow-up of 10 months (range 3-48) the incidence of
aGVHD and cGVHD were 195% and 135% respectively.
The probability of TRM was 104%. Patients grafted with
manipulated PBSC had the lowest TRM (43%). The relapse
incidence was 236.5%. High number of infused CD34 cells
(p0.066) and cGVHD (p0.01) was associated with a lesser
RI. The event-free survival was 697%. Fifteen patients died
due to: relapse or progressive disease (n9), aGVHD (n2),
cGVHD (n2) and other causes(n2). Conclusion: Fludara-
bine-based RIC provide a good alternative to “classical” my-
eloablative conditioning for allogeneic transplantation either
malignant or non-malignant disease in children.
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SYSTEMIC VIRAL AND FUNGAL INFECTIONS ARE NOT SIGNIFICANTLY
DECREASED FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM
CELL TRANSPLANTATION (RIALLOSCT) IN CHILDREN AND ADOLES-
CENT RECIPIENTS WITH MALIGNANT AND NONMALIGNANT DISEASES
Guerra, J.1, Satwani, P.1, Baldinger, L.1, van de Van, C.1, Roman, E.1,
Garvin, J.1, Bradley, M.B.1, Bhatia, M.1, George, D.1, Schwartz, J.3,
Hawkes, R.1, Wolownik, K.1, Foley, S.1, Morris, E.1, Militano, O.1,
Cairo, M.S.1,2,3 1Departments of Pediatrics; 2Medicine; 3Pathology,
New York-Presbyterian, Columbia University, New York, NY.
RIAlloSCT has been demonstrated to induce a high degree of
mixed donor chimerism and a signiﬁcant decrease in duration
and nadir of neutropenia in the early post allograft period
(Satwani/Cairo et al, BBMT, 2005). This reduction in duration
of neutropenia has translated into a signiﬁcant decrease in
bacteremia during the ﬁrst 30 days (Jungenhans et al, BBMT,
2002). It remains to be determined whether RIAlloSCT will also
result in a decrease in systemic viral and invasive fungal infec-
tions, which are more dependent on alteration in cellular im-
munity. From 1/2001 to 7/2006, 58 pediatric pts with median
age of 11.5 yrs (0.33-21) received RIAlloSCT for malignant
(n42) and non-malignant (n16) diseases. RI conditioning
was ﬂudarabine based 150-180 mg/m2  busulfan 6.4-12.8
mg/kg (n42), or cyclophosphamide 30-120 mg/kg (n14) or
melphalan 70 mg/m2 (n2)  ATG (n36) or alemtuzumab
(n8). Stem cell source consisted of UCB (n29), PBSC
(n21), BM (n8). Donor sources included HLA-match sib-
lings (n19), partially matched related (n6), or unrelated
(n33). All pts received tacrolimus and MMF as GVHD pro-
phylaxis (Osunkwo/Cairo et al, BBMT, 2004). CMV at risk
recipients received ganciclovir/foscarnet (Shereck/Cairo et al,
PBC, 2006) and all received antifungal prophylaxis with liposo-
mal amphotericin B until day 100. F/U 686  76 d. The
median time to myeloid engraftment was 16 d and incidence of
primary graft failure was 17.2%. Viral infections were present in
39 pts (67%) after a mean of 131  104 d. CMV reactivation
10%, adenovirus 17%, RSV 17%, inﬂuenza (A and B) 10%,
parainﬂuenza II and III 10%, BKV 17%, JCV 3%, HSV-1 12%,
VZV 7%, HHV-6 1.7%, and Calicivirus 1.7%. Two pts died,
1of CMV pneumonitis and 1 of RSV pneumonia. Fungal infec-
tions were reported in 12 pts (20%) after a mean of 204  188 d.
Six pts had invasive fungal infection (aspergillus 2). Incidence of
mortality secondary to viral and fungal infections was 5 and
17%, respectively. GVHD and its treatment with steroids were
present in 43% and 50% of patients with viral and invasive
fungal infections, respectively. The estimate 1 yr OS for all pts
was 65% (CI: 52-78) and for malignant and non-malignant pts
were 62% (CI: 47-78) and 73% (CI: 50-96), respectively. In
summary, these results suggest that RI conditioning probably
does not decrease the incidence of systemic viral and invasive
fungal infections, likely secondary to GVHD, particularly fol-
lowing unrelated HLA disparity donor allografts.
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RISK ADAPTED ALLOGENEIC STEM CELL TRANSPLANTATION (AL-
LOSCT) FOR ACQUIRED SEVERE APLASTIC ANEMIA (SAA) IN PEDIATRIC
RECIPIENTS
Guerra, J.1, Garvin, J.1, Baldinger, L.1, van de Ven, C.1, Roman, E.1,
Bhatia, M.1, Satwani, P.1, Bradley, M.B.1, George, D.1, Schwartz, J.3,
Morris, E.1, Hawkes, R.1, Wolownik, K.1, Foley, S.1, Militano, O.1,
Cairo, M.S.1,2,3 1Departments of Pediatrics; 2Medicine; 3Pathology,
New York-Presbsyterian, Columbia University, New York, NY.
AlloSCT from a HLA matched sibling donor is the preferred
treatment in children with acquired SAA in children. Alternative
donor HSCT gives inferior results, and has been reserved for
patients lacking matched family donors and unresponsive to
medical therapy. However, given the poor outcome of medical
therapy in subsets of patients with SAA, the advent less toxic
ﬂudarabine (FLU)-based non-myeloablative (NMA) regimens
(Chan et al, BMT, 2001), and our recent experience with UCBT
(Styczynski/Cairo et al, BMT, 2004), we investigated a risk-
adapted AlloSCT approach to 17 consecutive children with SAA
with matched related or unrelated donors between 01/2001 and
08/2006. There were 11 males and 6 females with median age of
11 years (range 4-16). Patients with fewer than 10 transfusions
underwent NMA AlloSCT with FLU 180 mg/m2, cyclophos-
phamide (CY) 60 mg/kg, and ATG 8 mg/kg (n8) or FLU 180
mg/m2, busulfan (BU) 12.8 mg/kg, and alemtuzumab 54 mg/m2
(n2). The remainder underwent myeloablative (MA) AlloSCT
with FLU 180 mg/m2, CY 200mg/kg and ATG 8mg/kg (n6)
or CY 200 mg/kg and ATG 8 mg/kg (n1). Stem cell sources
were BM (n12) from 6/6- (n9) or 5/6- (n2) matched family
donors or 9/10-matched unrelated donor (MUD) (n1), or
UCB (n5), either 6/6- (n1), 5/6- (n2), or 4/6-matched
(n2). All patients received tacrolimus and mycophenolate
mofetil as GVHD prophylaxis as we previously described (Os-
unkwo/Cairo et al, BBMT, 2004). The median time to myeloid
and platelet engraftment were 14 (9-30) and 40.5 (12-161) days,
respectively. 15 pts (88.2%) engrafted and 2 (11.8%) had sec-
ondary graft failure. Acute GVHD grade II-IV was observed in
35.3% of pts, whereas only 5.9 % developed chronic GVHD. 1
patient developed PTLD. 6 pts (35.3 %) died, multiorgan fail-
ure (n3), extensive AGVHD (n1), fungal infection (n1) and
thrombotic microangiopathy (n1). The probability of overall
survival (OS) for all patients was 60.9% (CI 95: 36.4-86.5). We
did not observe differences in OS according to donor type
(related vs. unrelated), intensity of conditioning regimen (MA
vs. NMA), or CMV status of donor and recipient. However, we
found a signiﬁcant difference in OS by degree of match (6/6 or
9/10 vs. 6/6) 77.8 % (CI 95: 50.6-100) vs. 33.3 % (CI 95:
0-71.1) (P0.05). In conclusion, risk-adapted AlloSCT is fea-
sible in children with newly diagnosed acquired SAA and further
investigation of this approach is warranted.
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